Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rectal Neoplasms | 32 | 2024 | 1156 | 3.270 |
Why?
|
Colorectal Surgery | 7 | 2020 | 122 | 2.650 |
Why?
|
Colectomy | 12 | 2021 | 686 | 1.850 |
Why?
|
Anus Neoplasms | 9 | 2024 | 329 | 1.600 |
Why?
|
Digestive System Surgical Procedures | 7 | 2020 | 571 | 0.860 |
Why?
|
Perineum | 6 | 2024 | 208 | 0.830 |
Why?
|
Rectum | 11 | 2023 | 891 | 0.810 |
Why?
|
Perioperative Care | 4 | 2019 | 1037 | 0.810 |
Why?
|
Adenocarcinoma | 18 | 2020 | 6340 | 0.810 |
Why?
|
Abdomen | 6 | 2019 | 1128 | 0.660 |
Why?
|
Postoperative Complications | 23 | 2024 | 15634 | 0.660 |
Why?
|
Abdominal Muscles | 1 | 2019 | 169 | 0.630 |
Why?
|
Length of Stay | 10 | 2020 | 6420 | 0.620 |
Why?
|
Colon | 8 | 2020 | 1791 | 0.600 |
Why?
|
Dendritic Cell Sarcoma, Interdigitating | 1 | 2017 | 3 | 0.590 |
Why?
|
Health Plan Implementation | 1 | 2020 | 335 | 0.560 |
Why?
|
Bupivacaine | 1 | 2019 | 411 | 0.530 |
Why?
|
Neoplasm Staging | 25 | 2023 | 11118 | 0.520 |
Why?
|
Colonic Neoplasms | 11 | 2021 | 2528 | 0.500 |
Why?
|
Appendiceal Neoplasms | 4 | 2019 | 155 | 0.480 |
Why?
|
Anal Canal | 5 | 2019 | 374 | 0.460 |
Why?
|
Diverticulitis | 3 | 2022 | 185 | 0.450 |
Why?
|
Constipation | 2 | 2015 | 564 | 0.430 |
Why?
|
Infection Control | 1 | 2020 | 983 | 0.420 |
Why?
|
Carcinoid Tumor | 3 | 2019 | 224 | 0.420 |
Why?
|
Tissue Adhesions | 2 | 2013 | 218 | 0.420 |
Why?
|
Appendectomy | 4 | 2020 | 433 | 0.410 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2021 | 4021 | 0.390 |
Why?
|
Colorectal Neoplasms | 12 | 2021 | 6919 | 0.370 |
Why?
|
Venous Thromboembolism | 2 | 2021 | 1868 | 0.350 |
Why?
|
Pain, Postoperative | 2 | 2020 | 1738 | 0.340 |
Why?
|
Analgesics, Opioid | 3 | 2020 | 3808 | 0.330 |
Why?
|
Stress, Physiological | 1 | 2017 | 1406 | 0.320 |
Why?
|
Academic Medical Centers | 2 | 2017 | 2757 | 0.320 |
Why?
|
Abdominal Pain | 2 | 2015 | 1071 | 0.320 |
Why?
|
Adenomatous Polyposis Coli | 2 | 2021 | 219 | 0.310 |
Why?
|
Neuroendocrine Tumors | 3 | 2019 | 641 | 0.310 |
Why?
|
Survival Rate | 20 | 2021 | 12727 | 0.290 |
Why?
|
Brachytherapy | 3 | 2007 | 1223 | 0.280 |
Why?
|
Neoadjuvant Therapy | 3 | 2023 | 2827 | 0.280 |
Why?
|
Surgical Flaps | 4 | 2024 | 1670 | 0.280 |
Why?
|
Informed Consent | 1 | 2013 | 1007 | 0.280 |
Why?
|
Hemorrhoids | 2 | 1999 | 19 | 0.270 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2019 | 517 | 0.270 |
Why?
|
Hyperthermia, Induced | 2 | 2021 | 417 | 0.270 |
Why?
|
Radiation Injuries | 2 | 2004 | 1191 | 0.270 |
Why?
|
Treatment Refusal | 2 | 2020 | 429 | 0.270 |
Why?
|
Databases, Factual | 8 | 2021 | 7969 | 0.270 |
Why?
|
Postoperative Period | 3 | 2020 | 1818 | 0.270 |
Why?
|
Surgical Wound Infection | 4 | 2019 | 1530 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2020 | 9278 | 0.250 |
Why?
|
Humans | 110 | 2024 | 761098 | 0.250 |
Why?
|
Combined Modality Therapy | 13 | 2021 | 8519 | 0.250 |
Why?
|
Middle Aged | 62 | 2023 | 220835 | 0.250 |
Why?
|
Retrospective Studies | 34 | 2024 | 80673 | 0.250 |
Why?
|
Crohn Disease | 3 | 2020 | 2279 | 0.250 |
Why?
|
Interleukin-23 | 1 | 2006 | 201 | 0.240 |
Why?
|
Ileum | 4 | 2020 | 557 | 0.240 |
Why?
|
Urinary Fistula | 1 | 2004 | 42 | 0.240 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2164 | 0.230 |
Why?
|
Triazines | 1 | 2006 | 311 | 0.230 |
Why?
|
Homeodomain Proteins | 3 | 2020 | 2413 | 0.230 |
Why?
|
Peritoneal Neoplasms | 2 | 2021 | 710 | 0.230 |
Why?
|
Rectal Fistula | 1 | 2004 | 75 | 0.230 |
Why?
|
Interleukin-12 | 1 | 2006 | 578 | 0.220 |
Why?
|
Hospitalization | 2 | 2020 | 10712 | 0.220 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2018 | 876 | 0.220 |
Why?
|
Aged | 44 | 2023 | 169266 | 0.210 |
Why?
|
Morpholines | 1 | 2006 | 581 | 0.210 |
Why?
|
Male | 64 | 2023 | 360675 | 0.210 |
Why?
|
Appendicitis | 3 | 2019 | 675 | 0.210 |
Why?
|
Laparoscopy | 6 | 2018 | 2030 | 0.210 |
Why?
|
Microsurgery | 1 | 2008 | 793 | 0.210 |
Why?
|
Iliac Artery | 1 | 2004 | 343 | 0.200 |
Why?
|
Colostomy | 2 | 2017 | 105 | 0.200 |
Why?
|
Ileostomy | 2 | 2017 | 121 | 0.190 |
Why?
|
Female | 62 | 2023 | 392458 | 0.190 |
Why?
|
Operating Rooms | 2 | 2020 | 790 | 0.180 |
Why?
|
Economics, Nursing | 1 | 2020 | 7 | 0.180 |
Why?
|
Colonic Diseases | 2 | 2019 | 201 | 0.180 |
Why?
|
Incidence | 9 | 2021 | 21357 | 0.170 |
Why?
|
Hemorrhage | 2 | 2004 | 3422 | 0.170 |
Why?
|
Duodenal Neoplasms | 1 | 2020 | 114 | 0.170 |
Why?
|
Economics, Pharmaceutical | 1 | 2020 | 87 | 0.170 |
Why?
|
Intestinal Neoplasms | 2 | 2020 | 314 | 0.170 |
Why?
|
Follow-Up Studies | 19 | 2019 | 39121 | 0.170 |
Why?
|
Lymph Nodes | 3 | 2020 | 3461 | 0.160 |
Why?
|
Healthcare Disparities | 3 | 2019 | 3352 | 0.160 |
Why?
|
Resuscitation Orders | 1 | 2021 | 270 | 0.160 |
Why?
|
Sigmoidoscopy | 1 | 2019 | 151 | 0.160 |
Why?
|
Reed-Sternberg Cells | 1 | 2019 | 72 | 0.160 |
Why?
|
Ileal Diseases | 1 | 2019 | 68 | 0.160 |
Why?
|
Orthopedic Equipment | 1 | 1998 | 22 | 0.160 |
Why?
|
Chemoprevention | 1 | 2021 | 325 | 0.160 |
Why?
|
Diagnosis-Related Groups | 1 | 2020 | 448 | 0.150 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1999 | 96 | 0.150 |
Why?
|
Treatment Outcome | 20 | 2020 | 64670 | 0.150 |
Why?
|
Inflammatory Bowel Diseases | 5 | 2020 | 2423 | 0.150 |
Why?
|
Omentum | 1 | 2019 | 167 | 0.150 |
Why?
|
Carcinoma, Large Cell | 1 | 2019 | 113 | 0.150 |
Why?
|
Goals | 1 | 2023 | 708 | 0.150 |
Why?
|
Varicose Veins | 1 | 1999 | 156 | 0.150 |
Why?
|
Preoperative Period | 1 | 2020 | 551 | 0.150 |
Why?
|
Time Factors | 10 | 2019 | 39953 | 0.150 |
Why?
|
Equipment and Supplies | 1 | 2020 | 273 | 0.150 |
Why?
|
Coccyx | 1 | 1997 | 13 | 0.140 |
Why?
|
Hypertension, Portal | 1 | 1999 | 227 | 0.140 |
Why?
|
Hernia, Inguinal | 1 | 2020 | 220 | 0.140 |
Why?
|
Abdominal Abscess | 1 | 2018 | 153 | 0.140 |
Why?
|
United States | 20 | 2022 | 72337 | 0.140 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2019 | 3512 | 0.140 |
Why?
|
Intraoperative Complications | 1 | 2004 | 1165 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 11732 | 0.140 |
Why?
|
Pelvis | 2 | 2024 | 734 | 0.140 |
Why?
|
Databases as Topic | 1 | 2019 | 473 | 0.140 |
Why?
|
Hyaluronic Acid | 2 | 2013 | 484 | 0.140 |
Why?
|
Carcinoma, Small Cell | 1 | 2019 | 420 | 0.130 |
Why?
|
Military Medicine | 1 | 2018 | 184 | 0.130 |
Why?
|
Leiomyosarcoma | 1 | 2020 | 422 | 0.130 |
Why?
|
Aged, 80 and over | 18 | 2020 | 58946 | 0.130 |
Why?
|
Liposomes | 1 | 2019 | 783 | 0.130 |
Why?
|
Disease-Free Survival | 5 | 2015 | 6817 | 0.130 |
Why?
|
Adult | 31 | 2023 | 221083 | 0.130 |
Why?
|
Prognosis | 12 | 2020 | 29672 | 0.130 |
Why?
|
Malnutrition | 1 | 2022 | 622 | 0.130 |
Why?
|
Anastomosis, Surgical | 5 | 2019 | 982 | 0.130 |
Why?
|
Patient Selection | 4 | 2020 | 4245 | 0.130 |
Why?
|
Morphine | 1 | 2019 | 656 | 0.120 |
Why?
|
Lymphoproliferative Disorders | 1 | 2019 | 530 | 0.120 |
Why?
|
Mesothelioma | 1 | 2021 | 807 | 0.120 |
Why?
|
Intraoperative Care | 1 | 1999 | 767 | 0.120 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 339 | 0.120 |
Why?
|
Documentation | 1 | 2021 | 898 | 0.120 |
Why?
|
Propensity Score | 2 | 2020 | 1913 | 0.120 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 3196 | 0.110 |
Why?
|
Drug Utilization | 1 | 2020 | 1188 | 0.110 |
Why?
|
Bacteria, Aerobic | 1 | 1993 | 24 | 0.110 |
Why?
|
Neoplasm Invasiveness | 4 | 2020 | 3591 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2008 | 646 | 0.110 |
Why?
|
Bacteria, Anaerobic | 1 | 1993 | 70 | 0.110 |
Why?
|
Clinical Trials as Topic | 3 | 2006 | 8000 | 0.110 |
Why?
|
Peritoneal Cavity | 1 | 2013 | 135 | 0.110 |
Why?
|
Radiotherapy, Adjuvant | 5 | 1999 | 1784 | 0.110 |
Why?
|
Patient Readmission | 5 | 2020 | 3268 | 0.110 |
Why?
|
Facility Design and Construction | 1 | 2013 | 85 | 0.110 |
Why?
|
Specialties, Surgical | 1 | 2017 | 389 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2019 | 614 | 0.100 |
Why?
|
Cytosine | 1 | 2013 | 212 | 0.100 |
Why?
|
Fluorouracil | 3 | 2008 | 1642 | 0.100 |
Why?
|
Surgery Department, Hospital | 1 | 2013 | 176 | 0.100 |
Why?
|
Ileus | 2 | 2016 | 66 | 0.100 |
Why?
|
Range of Motion, Articular | 1 | 1998 | 1590 | 0.100 |
Why?
|
Mitomycin | 2 | 2019 | 263 | 0.090 |
Why?
|
Quality Improvement | 4 | 2019 | 3801 | 0.090 |
Why?
|
Lymphoma | 1 | 2020 | 1898 | 0.090 |
Why?
|
Cell Differentiation | 3 | 2020 | 11505 | 0.090 |
Why?
|
Health Services Accessibility | 2 | 2019 | 5427 | 0.090 |
Why?
|
Joint Instability | 1 | 1998 | 801 | 0.090 |
Why?
|
Liver Neoplasms | 5 | 2021 | 4308 | 0.090 |
Why?
|
Survival Analysis | 7 | 2020 | 10083 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 1664 | 0.090 |
Why?
|
Postoperative Care | 1 | 2016 | 1469 | 0.090 |
Why?
|
Monocytes | 2 | 2021 | 2570 | 0.080 |
Why?
|
Knee Joint | 1 | 1998 | 1677 | 0.080 |
Why?
|
Arrhythmias, Cardiac | 1 | 2019 | 2247 | 0.080 |
Why?
|
Intestinal Obstruction | 2 | 2006 | 432 | 0.080 |
Why?
|
Cohort Studies | 6 | 2021 | 41486 | 0.080 |
Why?
|
Military Personnel | 1 | 2018 | 1246 | 0.080 |
Why?
|
Anesthesia | 1 | 2020 | 1591 | 0.080 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2019 | 1187 | 0.080 |
Why?
|
Tumor Microenvironment | 2 | 2020 | 3869 | 0.080 |
Why?
|
Hospitals, Community | 2 | 2021 | 365 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2000 | 0.080 |
Why?
|
Proportional Hazards Models | 5 | 2020 | 12467 | 0.080 |
Why?
|
Heart-Assist Devices | 1 | 2019 | 1288 | 0.080 |
Why?
|
Risk Factors | 11 | 2020 | 74219 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2019 | 677 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2020 | 3044 | 0.080 |
Why?
|
Intestinal Mucosa | 3 | 2014 | 3030 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2019 | 1846 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1923 | 0.070 |
Why?
|
Salvage Therapy | 2 | 2019 | 1264 | 0.070 |
Why?
|
Radiotherapy Dosage | 2 | 2008 | 2898 | 0.070 |
Why?
|
Remission Induction | 2 | 2006 | 2392 | 0.070 |
Why?
|
Interleukin-2 | 1 | 2013 | 1891 | 0.070 |
Why?
|
Chewing Gum | 1 | 2006 | 40 | 0.070 |
Why?
|
Intestine, Small | 3 | 2020 | 1207 | 0.070 |
Why?
|
Primary Health Care | 1 | 2023 | 4673 | 0.070 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2006 | 38 | 0.060 |
Why?
|
Hydrazones | 1 | 2006 | 103 | 0.060 |
Why?
|
Prostatic Neoplasms | 2 | 2007 | 11103 | 0.060 |
Why?
|
Medicaid | 1 | 2019 | 2814 | 0.060 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4908 | 0.060 |
Why?
|
Sepsis | 1 | 2018 | 2586 | 0.060 |
Why?
|
Carcinoma | 3 | 2007 | 2328 | 0.060 |
Why?
|
Preoperative Care | 1 | 2013 | 2242 | 0.060 |
Why?
|
Prospective Studies | 13 | 2019 | 54419 | 0.060 |
Why?
|
Dermoid Cyst | 1 | 2004 | 92 | 0.060 |
Why?
|
Muscle, Skeletal | 1 | 1999 | 4947 | 0.060 |
Why?
|
Logistic Models | 5 | 2020 | 13254 | 0.050 |
Why?
|
Macrophages | 1 | 2018 | 5754 | 0.050 |
Why?
|
Pancreatic Neoplasms | 2 | 2020 | 5366 | 0.050 |
Why?
|
Age Factors | 4 | 2020 | 18385 | 0.050 |
Why?
|
Clinical Protocols | 3 | 2017 | 1436 | 0.050 |
Why?
|
Dendritic Cells | 1 | 2014 | 2726 | 0.050 |
Why?
|
Tomography, Spiral Computed | 1 | 2004 | 273 | 0.050 |
Why?
|
Reoperation | 3 | 2018 | 4304 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2020 | 22157 | 0.050 |
Why?
|
Lipoma | 1 | 2004 | 293 | 0.050 |
Why?
|
Cell Line, Tumor | 4 | 2021 | 16947 | 0.050 |
Why?
|
Liver Transplantation | 1 | 1993 | 2329 | 0.050 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2004 | 328 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2020 | 12058 | 0.050 |
Why?
|
Anticoagulants | 1 | 2016 | 4795 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2021 | 383 | 0.050 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2004 | 592 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2004 | 858 | 0.040 |
Why?
|
Melanoma | 1 | 2018 | 5694 | 0.040 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2000 | 186 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 782 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2009 | 2218 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 8529 | 0.040 |
Why?
|
Critical Pathways | 1 | 2023 | 475 | 0.040 |
Why?
|
Pelvic Exenteration | 1 | 1999 | 21 | 0.040 |
Why?
|
Perioperative Period | 1 | 2020 | 252 | 0.040 |
Why?
|
Rectal Diseases | 1 | 2000 | 142 | 0.040 |
Why?
|
Collateral Ligaments | 1 | 1998 | 34 | 0.040 |
Why?
|
Hepatic Encephalopathy | 1 | 1999 | 143 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2021 | 428 | 0.040 |
Why?
|
Cecum | 1 | 2019 | 234 | 0.040 |
Why?
|
Administration, Oral | 1 | 2006 | 4014 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2021 | 716 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2005 | 1315 | 0.040 |
Why?
|
Surgical Wound Dehiscence | 1 | 2019 | 212 | 0.040 |
Why?
|
Biology | 1 | 2020 | 289 | 0.040 |
Why?
|
Hepatectomy | 1 | 2021 | 557 | 0.040 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2019 | 209 | 0.040 |
Why?
|
Young Adult | 3 | 2021 | 59199 | 0.040 |
Why?
|
Occult Blood | 1 | 2018 | 197 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 3689 | 0.040 |
Why?
|
Chemokines | 1 | 2021 | 956 | 0.040 |
Why?
|
Proctocolectomy, Restorative | 1 | 2019 | 190 | 0.030 |
Why?
|
Drug Therapy | 1 | 2020 | 503 | 0.030 |
Why?
|
Veterans Health | 1 | 2018 | 215 | 0.030 |
Why?
|
Morbidity | 1 | 2022 | 1750 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2021 | 821 | 0.030 |
Why?
|
Oligo-1,6-Glucosidase | 1 | 1995 | 7 | 0.030 |
Why?
|
Patients | 1 | 2023 | 906 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 841 | 0.030 |
Why?
|
Sucrase | 1 | 1995 | 51 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15308 | 0.030 |
Why?
|
Patient Preference | 1 | 2023 | 926 | 0.030 |
Why?
|
Age Distribution | 2 | 2019 | 2873 | 0.030 |
Why?
|
Stromal Cells | 1 | 2021 | 1329 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 996 | 0.030 |
Why?
|
Markov Chains | 1 | 2019 | 965 | 0.030 |
Why?
|
Confidence Intervals | 2 | 1998 | 2927 | 0.030 |
Why?
|
Thigh | 1 | 2016 | 239 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 26068 | 0.030 |
Why?
|
Quality of Life | 3 | 2019 | 13362 | 0.030 |
Why?
|
Phagocytosis | 1 | 2020 | 1525 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1089 | 0.030 |
Why?
|
Dehydration | 1 | 2016 | 216 | 0.030 |
Why?
|
Biopsy | 2 | 1998 | 6781 | 0.030 |
Why?
|
Colonic Polyps | 2 | 2000 | 553 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36418 | 0.030 |
Why?
|
Molecular Biology | 1 | 1998 | 573 | 0.030 |
Why?
|
Pyrimidines | 1 | 2006 | 3026 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6482 | 0.030 |
Why?
|
Insurance Claim Review | 1 | 2018 | 741 | 0.030 |
Why?
|
Suture Techniques | 1 | 1999 | 768 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1822 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2125 | 0.030 |
Why?
|
Time and Motion Studies | 1 | 2013 | 143 | 0.030 |
Why?
|
User-Computer Interface | 1 | 2000 | 1395 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2019 | 1076 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 2 | 1991 | 335 | 0.030 |
Why?
|
Prednisolone | 1 | 2014 | 324 | 0.030 |
Why?
|
Safety | 1 | 1998 | 1151 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2621 | 0.030 |
Why?
|
Colony Count, Microbial | 1 | 1993 | 328 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 1998 | 1702 | 0.030 |
Why?
|
Electrolytes | 1 | 1993 | 274 | 0.030 |
Why?
|
Methods | 1 | 1993 | 1063 | 0.030 |
Why?
|
Probability | 1 | 1998 | 2478 | 0.030 |
Why?
|
Therapeutic Irrigation | 1 | 1993 | 293 | 0.020 |
Why?
|
Tumor Burden | 1 | 2018 | 1892 | 0.020 |
Why?
|
Sensitivity and Specificity | 4 | 2006 | 14676 | 0.020 |
Why?
|
Qualitative Research | 1 | 2023 | 3016 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1723 | 0.020 |
Why?
|
Rectal Prolapse | 1 | 1992 | 33 | 0.020 |
Why?
|
Thoracoscopy | 1 | 1993 | 183 | 0.020 |
Why?
|
Cholangitis, Sclerosing | 1 | 1993 | 177 | 0.020 |
Why?
|
Reimbursement, Incentive | 1 | 2017 | 542 | 0.020 |
Why?
|
Liver Cirrhosis | 2 | 1999 | 1932 | 0.020 |
Why?
|
Administration, Topical | 1 | 2013 | 703 | 0.020 |
Why?
|
Minority Groups | 1 | 2019 | 1201 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 1993 | 287 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 1995 | 1168 | 0.020 |
Why?
|
Reference Values | 1 | 1998 | 4922 | 0.020 |
Why?
|
Aftercare | 1 | 1997 | 913 | 0.020 |
Why?
|
Equipment Design | 1 | 1998 | 3509 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2018 | 2381 | 0.020 |
Why?
|
Comorbidity | 1 | 2004 | 10514 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1602 | 0.020 |
Why?
|
Efficiency, Organizational | 1 | 2013 | 695 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5249 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3763 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3550 | 0.020 |
Why?
|
Fever | 1 | 2016 | 1618 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2013 | 858 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 1993 | 1187 | 0.020 |
Why?
|
Insurance, Health | 1 | 2020 | 2494 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2006 | 9001 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7574 | 0.020 |
Why?
|
Male Urogenital Diseases | 1 | 2007 | 48 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2004 | 4853 | 0.020 |
Why?
|
Data Collection | 1 | 2017 | 3319 | 0.020 |
Why?
|
Benchmarking | 1 | 2013 | 1045 | 0.020 |
Why?
|
Body Mass Index | 1 | 2005 | 12951 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2018 | 1937 | 0.020 |
Why?
|
Recovery of Function | 1 | 2017 | 2981 | 0.020 |
Why?
|
Poverty | 1 | 2019 | 2692 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4565 | 0.020 |
Why?
|
Blotting, Western | 1 | 2014 | 5033 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2014 | 2200 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10552 | 0.020 |
Why?
|
Diagnostic Imaging | 2 | 1998 | 3535 | 0.020 |
Why?
|
Unnecessary Procedures | 1 | 2009 | 417 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 1997 | 1923 | 0.020 |
Why?
|
Computer Simulation | 1 | 2019 | 6225 | 0.020 |
Why?
|
Methylhydrazines | 1 | 1984 | 6 | 0.020 |
Why?
|
Dimethylhydrazines | 1 | 1984 | 12 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2006 | 510 | 0.010 |
Why?
|
Catheterization, Central Venous | 1 | 2009 | 526 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10421 | 0.010 |
Why?
|
Societies, Medical | 1 | 2017 | 3923 | 0.010 |
Why?
|
Device Removal | 1 | 2009 | 630 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2014 | 2160 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2014 | 3210 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10203 | 0.010 |
Why?
|
Fallopian Tubes | 1 | 2004 | 178 | 0.010 |
Why?
|
Patient Discharge | 1 | 2016 | 3441 | 0.010 |
Why?
|
Risk Assessment | 2 | 2019 | 24013 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2013 | 6305 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14393 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2009 | 1303 | 0.010 |
Why?
|
Mass Screening | 1 | 2018 | 5425 | 0.010 |
Why?
|
Carcinogens | 1 | 1984 | 452 | 0.010 |
Why?
|
Ovariectomy | 1 | 2004 | 613 | 0.010 |
Why?
|
Cell Movement | 1 | 2014 | 5195 | 0.010 |
Why?
|
Placebos | 1 | 2006 | 1666 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10758 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7567 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1994 | 2293 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2013 | 3048 | 0.010 |
Why?
|
Registries | 1 | 1997 | 8236 | 0.010 |
Why?
|
Evaluation Studies as Topic | 2 | 1994 | 1624 | 0.010 |
Why?
|
Ovary | 1 | 2004 | 957 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 3419 | 0.010 |
Why?
|
International Cooperation | 1 | 2006 | 1423 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2009 | 2165 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2007 | 1201 | 0.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 1984 | 976 | 0.010 |
Why?
|
Adolescent | 3 | 2006 | 88271 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 18926 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 2007 | 2465 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2006 | 6224 | 0.010 |
Why?
|
Signal Transduction | 1 | 2020 | 23415 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 30006 | 0.010 |
Why?
|
Age of Onset | 1 | 2004 | 3307 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2004 | 12975 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2000 | 20600 | 0.010 |
Why?
|
Intestinal Polyps | 1 | 1995 | 105 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 1997 | 1008 | 0.010 |
Why?
|
Hyperplasia | 1 | 1995 | 1150 | 0.010 |
Why?
|
Laparotomy | 1 | 1994 | 456 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 1984 | 3092 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13630 | 0.010 |
Why?
|
Sex Distribution | 1 | 1995 | 2278 | 0.010 |
Why?
|
Palliative Care | 1 | 2004 | 3593 | 0.000 |
Why?
|
Folic Acid | 1 | 1995 | 1323 | 0.000 |
Why?
|
Animals | 2 | 2018 | 168083 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 1991 | 13382 | 0.000 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1995 | 2820 | 0.000 |
Why?
|
1,2-Dimethylhydrazine | 1 | 1984 | 8 | 0.000 |
Why?
|
Rats, Inbred WF | 1 | 1984 | 140 | 0.000 |
Why?
|
Stomach Neoplasms | 1 | 1993 | 1458 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1995 | 11066 | 0.000 |
Why?
|
Alcohol Drinking | 1 | 1995 | 4028 | 0.000 |
Why?
|
Neoplasms, Experimental | 1 | 1984 | 1225 | 0.000 |
Why?
|
Recurrence | 1 | 1991 | 8456 | 0.000 |
Why?
|
Liver | 1 | 1994 | 7513 | 0.000 |
Why?
|
Smoking | 1 | 1995 | 9055 | 0.000 |
Why?
|
Prevalence | 1 | 1995 | 15717 | 0.000 |
Why?
|
Diet | 1 | 1995 | 8047 | 0.000 |
Why?
|
Rats | 1 | 1984 | 23713 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 1984 | 9185 | 0.000 |
Why?
|
Phenotype | 1 | 1984 | 16572 | 0.000 |
Why?
|